LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has announced that it is working toward listing its commons shares on the Nasdaq Capital Market; the company is anticipates submitting its application before the end of this year. In the announcement, LexaGene noted that a successful NASDAQ listing will make its shares more accessible to retail and institutional investors both in the United States and internationally; the company recognized that the Nasdaq hosts the best global biotech and life science companies. To prepare for the listing application, LexaGene has reserved the ticker symbol LXG for 24 months and has retained the services of law firm Latham & Watkins LLP. The firm will assist in preparation for filing the Registration and Annual Report for Canadian Securities Form (Form 40-F) with the US Securities and Exchange Commission (“SEC”). At the firm, LexaGene is working with Peter Handrinos, who has impressive experience in advising life science and technology companies on securities law matters and has worked with many companies in the process of going public on U.S. exchanges. LexaGene has also engaged RSM US LLP for audit, tax and consulting services. “We anticipate LexaGene will grow in size and strength in the coming months and years,” said LexaGene CEO and founder Dr. Jack Regan in the press release. “Part of our growth strategy is to make the company more accessible to U.S. investors. I’m very pleased to have engaged two exceptional firms to help guide us through this process. A successful Nasdaq listing makes us more attractive to institutional investors, and eligible for inclusion in key indexes and ETFs.”
To view the full press release, visit https://ibn.fm/kkZbg
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. LexaGene’s MiQLab(TM) system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.
NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.